Simcere to go private after chairman-led group ups offer
This article was originally published in Scrip
Executive Summary
Following a non-binding buyout proposal from its chairman and other investors earlier this year, the US-listed Chinese pharma concern Simcere Pharmaceutical Group (SPG) has entered into a definitive agreement to delist from the New York Stock Exchange and go private.